Chevron Shuts-In Production at Gulf of Mexico Sites Due to Tropical Storm Rafael-February 2024-www.financetom.com

Chevron Shuts-In Production at Gulf of Mexico Sites Due to Tropical Storm Rafael

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Chevron Shuts-In Production at Gulf of Mexico Sites Due to Tropical Storm Rafael

Nov 9, 2024 11:01 AM

02:45 PM EST, 11/05/2024 (MT Newswires) -- Chevron ( CVX ) said Tuesday it is shutting-in production at the Gulf of Mexico facilities it operates in preparation for Tropical Storm Rafael.

All associated personnel will be transported to shore, the company said.

Price: 152.77, Change: -1.20, Percent Change: -0.78

Previous page： Pfizer Eyed By Starboard for Shareholder Rights Campaign Next page： BRIEF-Comstock To Acquire Quantum Generative Materials

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Pfizer Eyed By Starboard for Shareholder Rights Campaign

Oct 7, 2024

06:44 AM EDT, 10/07/2024 (MT Newswires) -- Pfizer ( PFE ) may become the target of a shareholder campaign led by Starboard Value, which has taken a $1 billion stake in the company, multiple news outlets reported Sunday. Reuters reported that Starboard, an activist investment advisory firm, wants to improve Pfizer's ( PFE ) performance and has already approached former...

BRIEF-Comstock To Acquire Quantum Generative Materials

Oct 7, 2024

Oct 7 (Reuters) - Comstock Inc ( LODE ): * COMSTOCK TO ACQUIRE QUANTUM GENERATIVE MATERIALS LLC * COMSTOCK TO ACQUIRE QUANTUM GENERATIVE MATERIALS LLC * COMSTOCK: CO, GENMAT AGREED TO TERMINATE EACH OF THEIR PRIOR INVESTMENT AGREEMENTS AS PART OF NEW ACQUISITION AGREEMENT Source text for Eikon: Further company coverage: ...

CAMP4 Therapeutics seeks up to $283 mln valuation in US IPO

Oct 7, 2024

Oct 7 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting a valuation of up to $283 million in its initial public offering in the United States. The company will join a pack of biotech firms that have listed their shares recently as a long-awaited policy-easing cycle begins. Startups are...

CAMP4 Therapeutics seeks up to $283 million valuation in US IPO

Oct 7, 2024

(Reuters) - CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting a valuation of up to $283 million in its initial public offering in the United States. The company will join a pack of biotech firms that have listed their shares recently as a long-awaited policy-easing cycle begins. Startups are also looking...